We serve Chemical Name:4-(3-methylpiperidin-1-yl)-1-(2,4,6-trimethoxyphenyl)butan-1-one CAS:92268-40-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-(3-methylpiperidin-1-yl)-1-(2,4,6-trimethoxyphenyl)butan-1-one
CAS.NO:92268-40-1
Synonyms:4-(3-Methyl-1-piperidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone;Perfomedil;4-(1-Piperidinyl-3-methyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone;Perfomedilum;UNII-8A8NY1Z12E;Perfomedil [INN];Perfomedilum [INN-Latin];1-Butanone,4-(3-methyl-1-piperidinyl)-1-(2,4,6-trimethoxyphenyl)
Molecular Formula:C19H29NO4
Molecular Weight:335.43800
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:473.3ºC at 760 mmHg
Density:1.049g/cm3
Index of Refraction:1.505
PSA:48.00000
Exact Mass:335.21000
LogP:3.34510
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-(3-Methyl-1-piperidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Butanone,4-(3-methyl-1-piperidinyl)-1-(2,4,6-trimethoxyphenyl) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Perfomedil Use and application,UNII-8A8NY1Z12E technical grade,usp/ep/jp grade.
Related News: During a conference call Thursday, Wall Street analysts piled into AstraZeneca’s China performance, pressing management on whether the company can sustain its double-digit sales growth in the country. 4-[1-[(4-Amino-phenyl)-hydrazonomethyl]-2-oxo-prop-(E)-ylidene]-5-methyl-2-phenyl-2,4-dihydro-pyrazol-3-one manufacturers Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit bis(n-butylamine)(phthalocyaninato)ruthenium suppliers The manufacturing chief pointed to some of the cutting-edge technology Takeda will roll out at the upgraded facility, such as automation and robotics, plus virtual reality equipment and training. 2-acetylamino-4,5-dibromo-benzoic acid vendor & factory.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit bis(n-butylamine)(phthalocyaninato)ruthenium suppliers The manufacturing chief pointed to some of the cutting-edge technology Takeda will roll out at the upgraded facility, such as automation and robotics, plus virtual reality equipment and training. 2-acetylamino-4,5-dibromo-benzoic acid vendor & factory.
